跳至主要内容
临床试验/ISRCTN38983527
ISRCTN38983527已完成不适用

Phase I/II single-arm interventional pilot study of capecitabine with or without vinorelbine after sequential dose-dense epirubicin and paclitaxel in high-risk early breast cancer

AGO Breast Study Group (Arbeitsgeinschaft für Gynäkolgische Onkologie) (Germany)0 个研究点目标入组 50 人开始时间: 2009年9月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
Female

入选标准

  • 1. Aged 18 to 65 years, female
  • 2. Histologically confirmed stage II/IIIA breast cancer with four or more positive axillary lymph nodes
  • 3. Had undergone surgery (complete surgical resection [R0] of breast tumour and axilla) before inclusion in the study
  • 4. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
  • 5. Left ventricular ejection fraction within the normal institutional range
  • 6. Adequate haematological, renal and hepatic function
  • 7. Provided written informed consent

排除标准

  • 1. Inflammatory breast cancer
  • 2. Received neoadjuvant endocrine therapy, chemotherapy or radiotherapy
  • 3. Known dihydropyrimidine dehydrogenase deficiency
  • 4. Creatinine clearance less than 30 mL/min
  • 5. Impaired organ function
  • 6. Metastatic disease

研究者

发起方
AGO Breast Study Group (Arbeitsgeinschaft für Gynäkolgische Onkologie) (Germany)

相似试验